CLRB News - Candlesense

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and ...

What are the key risks (clinical, regulatory, financial) that could affect the success of the Iopofosine program? What is the likely impact on analyst consensus estimates and target price after this corporate update? How might the outcome of the confirmatory trial affect the company’s long‑term strategic positioning and partnership opportunities?

Earnings

13 days ago

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commerc...

How do operating expense trends and R&D spending this quarter compare to historical levels and to peers? What potential dilution could result from upcoming financing activities or option exercises? Are there any regulatory milestones, FDA meetings, or other key dates scheduled in the near term?

Earnings

20 days ago

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...

Stock split

2 months ago